111.04 0.00 (0.00%)
After hours: 4:15PM EST
|Bid||111.09 x 800|
|Ask||111.09 x 800|
|Day's Range||110.90 - 111.89|
|52 Week Range||81.66 - 114.46|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||31.54|
|Forward Dividend & Yield||2.16 (1.91%)|
|1y Target Est||N/A|
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.
DUBLIN, Dec. 06, 2019 -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share,.
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 6,232,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD.
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%;.
The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable.
DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra™ Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular (AV) block. The results from the MARVEL 2 study will be presented Nov. 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions and were published today in JACC: Clinical Electrophysiology.
DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT™ Admiral™ drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Professor Thomas Zeller, M.D., director of the Department of Angiology at Universitaets-Herzzentrum, Freiburg-Bad Krozingen, Germany, presented the new, four-year results from the full clinical cohort of the IN.PACT Global Study. The results are the first four-year, real-world, fully adjudicated DCB data to be presented in a scientific congress.
Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2020 on Tuesday, November 19, 2019. The news release will include summary financial information for the company’s second quarter of fiscal year 2020, which ended on Friday, October 25, 2019. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2020.
Medtronic plc (MDT) today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion™ thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following FDA and CE Mark approvals in late 2018. The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant™ Captivia™ thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.
Medtronic plc (MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy at the Samsung Developers Conference in San Jose, Calif. The new programmer – which received U.S. Food and Drug Administration (FDA) approval on July 3, 2019 – leverages a user-friendly, custom-configured Samsung mobile device which allows patients to manage their therapy more simply and discreetly. To date, more than 150,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions. “It is important for patients to have access to advanced technology for user-friendly therapy management at home,” says Sandeep Thakkar, D.O., neurologist and movement disorder specialist at Hoag’s Pickup Family Neurosciences Institute.
Medtronic plc (MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Medtronic Fully Implantable Left Ventricular Assist Device (LVAD) for patients with advanced heart failure, currently in development. Currently, LVAD systems include an implanted heart pump to increase the amount of blood that circulates through the body. The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
Medtronic plc (MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH) within the Cardiac and Vascular Group of Medtronic, has been named Executive Vice President (EVP) and Group President of Medtronic Diabetes, effective today. Salmon will serve on the company’s Executive Committee and succeeds Hooman Hakami, who is leaving Medtronic.
Medtronic plc (MDT), the global leader in medical technology, today announced the launch of GI Genius™ intelligent endoscopy module at UEG Week in Barcelona, Spain. The GI Genius™ module is the first system worldwide using artificial intelligence to detect colorectal polyps. It provides physicians with a powerful new solution in the fight against colorectal cancer.
DUBLIN, Oct. 09, 2019 -- Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) has classified the company’s voluntary field action initiated in.
Medtronic plc (MDT) today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm (TAAA). A TAAA is a complex condition causing a bulging of the aorta, which extends from the chest down into to the abdomen.
DUBLIN, Oct. 07, 2019 -- Medtronic plc (NYSE:MDT) today announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter.
Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI.
Medtronic plc (MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid™ transcatheter mitral valve replacement (TMVR) system using a minimally-invasive transfemoral access approach. This announcement builds upon primary endpoint outcomes of the Intrepid TMVR clinical trial (APOLLO) using the transapical approach published in the Journal of the American College of Cardiology, the first-ever trial approved by the FDA to evaluate the safety and efficacy of a TMVR system. The prospective, multi-center, non-randomized EFS will evaluate the safety and performance of the Intrepid TMVR System with the transfemoral approach in patients with severe, symptomatic mitral regurgitation (MR) who are ineligible for conventional mitral valve surgery.
DUBLIN and SAN FRANCISCO, Sept. 26, 2019 -- Medtronic plc (NYSE:MDT) announced today late-breaking clinical data from the Onyx ONE Global Study, representing the first.
Medtronic plc (MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft in Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. A TLIF is a type of surgery that fuses – or joins – bones of the spine through a posterior approach.
michelson_logo Delivers the Industry’s Most Complete Portfolio of Implants, Biologics, Imaging, Navigation, Robotics, and Surface Technologies Designed to Transform.
Medtronic plc (MDT), a global leader in heart valve therapies, today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut™ PRO+ TAVR System – a new-generation Medtronic TAVR system that builds off the proven self-expanding, supra-annular Evolut TAVR platform. The Evolut PRO+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest indicated patient treatment range and the lowest delivery profile currently on the market. The launch comes on the heels of the FDA’s recent indication expansion for the Evolut TAVR platform to treat patients with symptomatic severe aortic stenosis at a low risk of surgical mortality, the final surgical risk category to be approved for TAVR.
The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. “The Time in Range clinical guidelines recommend that the target of effective diabetes management is the range of 70-180 mg/dL (3.9-10mmol/L) for at least 70% of time.
Medtronic plc (MDT), the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans.